Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne, and I will be your conference ...

Your fingernails do more than just add to your appearance—they can serve as a window into your overall health. Changes in color, texture, or shape might signal underlying conditions that need ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the ...

Zenas Founder and Chief Executive Officer, Lonnie Moulder highlighted the company’s progress across various goals in 2024, ...

Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026. Neurology Program: ...

Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...

Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications.

Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, ...